Paul Lochhead1, Hamed Khalili1, Ashwin N Ananthakrishnan1, James M Richter2, Andrew T Chan3. 1. Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: achan@mgh.harvard.edu.
Abstract
BACKGROUND & AIMS: There is evidence that immune dysfunction precedes symptoms of inflammatory bowel disease (IBD) by several years. Characterization of preclinical systemic inflammation could contribute to the understanding of the biology of IBD and, ultimately, facilitate development of strategies for early disease detection and intervention. We evaluated associations between circulating levels of interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP) and diagnosis of incident Crohn's disease (CD) or ulcerative colitis (UC). METHODS: We conducted a nested case-control study of participants enrolled in 2 population-based, nationwide, prospective cohort studies (the Nurses' Health Study and the Nurses' Health Study II). We analyzed blood specimens, collected before diagnosis, from 83 persons with CD, 90 persons with UC, and 344 matched individuals without IBD (control subjects). Plasma levels of hsCRP and IL6 were measured. We investigated associations between each inflammatory marker and IBD risk using multivariable logistic regression models to adjust for potential confounding exposures. RESULTS: Compared with the lowest quintile of IL6 level, the highest quintile was associated with an odds ratio (OR) of 4.68 (95% confidence interval, 1.91-11.46) for CD (Ptrend < .001) and an OR of 3.43 (95% confidence interval, 1.44-8.15) for UC (Ptrend = .004). The highest quintile of hsCRP level, compared with the lowest quintile, was associated with an OR of 2.82 (95% confidence interval, 1.15-6.87) for CD (Ptrend = .019) and an OR of 1.79 (95% confidence interval, 0.80-3.99) for UC (Ptrend = .015). CONCLUSIONS: Plasma levels of IL6 and hsCRP before diagnosis are associated with risk of incident CD and UC. Subclinical levels of systemic inflammation may be a feature of an early disease state that precedes the development of symptomatic IBD.
BACKGROUND & AIMS: There is evidence that immune dysfunction precedes symptoms of inflammatory bowel disease (IBD) by several years. Characterization of preclinical systemic inflammation could contribute to the understanding of the biology of IBD and, ultimately, facilitate development of strategies for early disease detection and intervention. We evaluated associations between circulating levels of interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP) and diagnosis of incident Crohn's disease (CD) or ulcerative colitis (UC). METHODS: We conducted a nested case-control study of participants enrolled in 2 population-based, nationwide, prospective cohort studies (the Nurses' Health Study and the Nurses' Health Study II). We analyzed blood specimens, collected before diagnosis, from 83 persons with CD, 90 persons with UC, and 344 matched individuals without IBD (control subjects). Plasma levels of hsCRP and IL6 were measured. We investigated associations between each inflammatory marker and IBD risk using multivariable logistic regression models to adjust for potential confounding exposures. RESULTS: Compared with the lowest quintile of IL6 level, the highest quintile was associated with an odds ratio (OR) of 4.68 (95% confidence interval, 1.91-11.46) for CD (Ptrend < .001) and an OR of 3.43 (95% confidence interval, 1.44-8.15) for UC (Ptrend = .004). The highest quintile of hsCRP level, compared with the lowest quintile, was associated with an OR of 2.82 (95% confidence interval, 1.15-6.87) for CD (Ptrend = .019) and an OR of 1.79 (95% confidence interval, 0.80-3.99) for UC (Ptrend = .015). CONCLUSIONS: Plasma levels of IL6 and hsCRP before diagnosis are associated with risk of incident CD and UC. Subclinical levels of systemic inflammation may be a feature of an early disease state that precedes the development of symptomatic IBD.
Authors: Hamed Khalili; Leslie M Higuchi; Ashwin N Ananthakrishnan; James M Richter; Diane Feskanich; Charles S Fuchs; Andrew T Chan Journal: Gut Date: 2012-05-22 Impact factor: 23.059
Authors: Fiona D M van Schaik; Bas Oldenburg; Andrew R Hart; Peter D Siersema; Stefan Lindgren; Olof Grip; Birgit Teucher; Rudolf Kaaks; Manuela M Bergmann; Heiner Boeing; Franck Carbonnel; Prevost Jantchou; Marie-Christine Boutron-Ruault; Anne Tjønneland; Anja Olsen; Francesca L Crowe; Petra H M Peeters; Martijn G H van Oijen; H Bas Bueno-de-Mesquita Journal: Gut Date: 2012-07-26 Impact factor: 23.059
Authors: Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Xiaomei Liao; Leslie M Higuchi; Charles S Fuchs; Donna Spiegelman; James M Richter; Joshua R Korzenik; Andrew T Chan Journal: BMJ Date: 2013-11-14
Authors: James R Irwin; Emma Ferguson; Lisa A Simms; Katherine Hanigan; James D Doecke; Daman Langguth; Ashley Arnott; Graham Radford-Smith Journal: Dig Dis Sci Date: 2018-11-26 Impact factor: 3.199
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; Mingyang Song; Leslie M Higuchi; Paul Lochhead; James M Richter; Andrew T Chan Journal: Inflamm Bowel Dis Date: 2017-11 Impact factor: 5.325
Authors: Wenjie Ma; Manol Jovani; Long H Nguyen; Fred K Tabung; Mingyang Song; Po-Hong Liu; Yin Cao; Idy Tam; Kana Wu; Edward L Giovannucci; Lisa L Strate; Andrew T Chan Journal: Clin Gastroenterol Hepatol Date: 2019-11-08 Impact factor: 11.382
Authors: Curtis Huttenhower; Andrew T Chan; Wenjie Ma; Long H Nguyen; Mingyang Song; Dong D Wang; Eric A Franzosa; Yin Cao; Amit Joshi; David A Drew; Raaj Mehta; Kerry L Ivey; Lisa L Strate; Edward L Giovannucci; Jacques Izard; Wendy Garrett; Eric B Rimm Journal: Genome Med Date: 2021-06-17 Impact factor: 11.117